AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15625792 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group (n = 31)
Number of subjects: 61
Study 15625792 — intervention group
Group type: COMPARATOR
Intervention: Focalization group (n = 30)
Number of subjects: 61
Study 11208684 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator therapy
Number of subjects: 440
Study 11208684 — intervention group
Group type: COMPARATOR
Intervention: Unstable VT (control group)
Number of subjects: 440
Study 11208684 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for baseline and treatment differences
Number of subjects: 440
Study 9686850 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drops
Number of subjects: 43
Study 9686850 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 43
Study 9453072 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of apomorphine at 250 microA.cm‐2
Number of subjects: 10
Study 9453072 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of apomorphine at 375 microA.cm‐2
Number of subjects: 10
Study 9453072 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive application of apomorphine
Number of subjects: 10
Study 9453072 — intervention group
Group type: EXPERIMENTAL
Intervention: Current delivery
Number of subjects: 10
Study 9453072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical deconvolution of profiles
Number of subjects: 10
Study 1764941 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 30 micrograms/day (LN 30)
Number of subjects: 0
Study 1764941 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone 350 micrograms/day (NE 350)
Number of subjects: 0
Study 6299620 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of the met-enkephalin analogue, DAMME
Number of subjects: 0
Study 6299620 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of the opiate antagonist, naloxone
Number of subjects: 0
Study 6299620 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia (0.15 u/kg) or naloxone (25 mg)
Number of subjects: 0
Study 29607741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric quinine-hydrochloride (QHCl, 10 µmol/kg)
Number of subjects: 15
Study 29607741 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 28671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended visitation model (12 hr/d)
Number of subjects: 286
Study 28671901 — intervention group
Group type: COMPARATOR
Intervention: Restricted visitation model (4.5 hr/d)
Number of subjects: 286
Study 26550976 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma follow-up unit
Number of subjects: 815
Study 26550976 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 815
Study 25171216 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training and anodal stimulation of the primary motor cortex
Number of subjects: 24
Study 25171216 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training and placebo transcranial direct‐current stimulation
Number of subjects: 24
Study 22217196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 219
Study 22217196 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 219
Study 22217196 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI <30)
Number of subjects: 219
Study 20667840 — intervention group
Group type: EXPERIMENTAL
Intervention: Looped NGT feeding
Number of subjects: 104
Study 20667840 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive dressing
Number of subjects: 104
Study 17405568 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 0
Study 17405568 — intervention group
Group type: EXPERIMENTAL
Intervention: Resynchronization therapy
Number of subjects: 0
Study 17405568 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term circulatory assistance
Number of subjects: 0
Study 15618785 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol bolus of 1 mg/kg followed by a continuous infusion of 150 microg.kg.min
Number of subjects: 10
Study 15618785 — intervention group
Group type: COMPARATOR
Intervention: No beta‐blockade (control)
Number of subjects: 10
Study 12477060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene gel 0.1% b.i.d. for eight consecutive weeks
Number of subjects: 12
Study 12477060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9174183 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at a dose of 2.8 to 3.0 mg/kg
Number of subjects: 10
Study 9174183 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate at a standard dose of 1.0 mg/kg
Number of subjects: 10
Study 9174183 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 10
Study 8417638 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression or proportional hazards analysis
Number of subjects: 60
Study 3096782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTC) administered orally in daily doses from 20 to 7.5 mg for 10 weeks
Number of subjects: 10
Study 3096782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28587472 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 20
Study 28587472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 27332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 225
Study 27332626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 24819106 — intervention group
Group type: EXPERIMENTAL
Intervention: Translumbar and transsacral magnetic stimulation
Number of subjects: 70
Study 22469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic HIPEC in a neo-adjuvant setting (12 patients)
Number of subjects: 31
Study 22469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic HIPEC in an adjuvant setting (19 patients)
Number of subjects: 31
Study 20707784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 243
Study 20707784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 20707784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline with high 'drive' scores on the BAS
Number of subjects: 243
Study 20707784 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high 'drive' scores on the BAS
Number of subjects: 243
Study 20707784 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline with low 'drive' scores on the BAS
Number of subjects: 243
Study 20707784 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low 'drive' scores on the BAS
Number of subjects: 243
Study 18517143 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training-enhanced program (TR+ST), n = 10
Number of subjects: 20
Study 18517143 — intervention group
Group type: COMPARATOR
Intervention: Traditional pulmonary rehabilitation program (TR), n = 10
Number of subjects: 20
Study 18517143 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training-enhanced program (TR+ST)
Number of subjects: 20
Study 15851647 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24897
Study 15851647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24897
Study 15851647 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 24897
Study 12455427 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session cognitive-behavioral therapy (CBT) in conjunction with usual TMD treatment
Number of subjects: 0
Study 12455427 — intervention group
Group type: COMPARATOR
Intervention: Usual conservative treatment by TMD specialist dentists
Number of subjects: 0
Study 10501817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) for 1 day (short-term treatment)
Number of subjects: 13
Study 10501817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) over a period of 28 days (long-term treatment)
Number of subjects: 13
Study 10501817 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (for 5 h) for 1 day (control treatment)
Number of subjects: 13
Study 10501817 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion over a period of 28 days (placebo treatment)
Number of subjects: 13
Study 8931888 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained release formulation of diltiazem (120 mg)
Number of subjects: 18
Study 8931888 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of diltiazem (120 mg)
Number of subjects: 18
Study 8931888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 1320559 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 1320559 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study 6435999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopirazepam
Number of subjects: 0
Study 6435999 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 6435999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30333359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg twice a day
Number of subjects: 64
Study 30333359 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid microinjections (4 mg/ml) monthly
Number of subjects: 64
Study 29500065 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75mg/m2) as first-line chemotherapy
Number of subjects: 571
Study 29500065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25mg/m2) as first-line chemotherapy
Number of subjects: 571
Study 29500065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 or 25mg/m2) as second-line chemotherapy
Number of subjects: 571
Study 29500065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PSA response
Number of subjects: 571
Study 26860838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DATG (group 1)
Number of subjects: 36
Study 26860838 — intervention group
Group type: COMPARATOR
Intervention: CT (group 2)
Number of subjects: 36
Study 25249651 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51
Study 25249651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22374059 — intervention group
Group type: EXPERIMENTAL
Intervention: Local pressure with gauze soaked with tranexamic acid
Number of subjects: 23
Study 22374059 — intervention group
Group type: COMPARATOR
Intervention: Local pressure with gauze without tranexamic acid
Number of subjects: 23
Study 21344797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis L. (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570
Study 21344797 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised purified flavanoid fraction (MPFF) (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570
Study 21344797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Number of subjects: 570
Study 16791905 — intervention group
Group type: COMPARATOR
Intervention: New treatment
Number of subjects: 0
Study 16791905 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 16236850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted medical management (MM)
Number of subjects: 151
Study 16236850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted collaborative management (CM)
Number of subjects: 151
Study 16236850 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 151
Study 12147790 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor antagonists (ARB)
Number of subjects: 304
Study 12147790 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control strategies
Number of subjects: 304
Study 12147790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (AHM) increase
Number of subjects: 304
Study 12147790 — intervention group
Group type: COMPARATOR
Intervention: No AHM increase
Number of subjects: 304
Study 12147790 — intervention group
Group type: COMPARATOR
Intervention: ACEI or ARB non-use
Number of subjects: 304
Study 9504938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 500 mg once daily
Number of subjects: 293
Study 9504938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 1000 mg twice daily
Number of subjects: 293
Study 9504938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 293
Study 9504938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 7635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ultrasound estimation of fetal weight at 37 weeks of gestation
Number of subjects: 1000
Study 7635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ultrasound estimations of fetal weight (at 28, 31, 34, and 37 weeks)
Number of subjects: 1000
Study 7635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear extrapolation from two estimates
Number of subjects: 1000
Study 7635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapolation by a second order polynomial fitted to four estimates
Number of subjects: 1000
Study 2468148 — intervention group
Group type: EXPERIMENTAL
Intervention: TX mode (rate responsive pacing)
Number of subjects: 18
Study 2468148 — intervention group
Group type: COMPARATOR
Intervention: VVI mode (fixed rate ventricular inhibited pacing)
Number of subjects: 18
Study 1152314 — intervention group
Group type: EXPERIMENTAL
Intervention: Puppet therapy (puppet show designed to familiarize patients with hospital routines and procedures)
Number of subjects: 43
Study 1152314 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (control)
Number of subjects: 43
Study 28371025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, taken 1 hour before sexual activity, adjustable to 100 or 25 mg)
Number of subjects: 9413
Study 26521575 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp electric acupuncture (EA) under anatomic orientation combined with rehabilitation training
Number of subjects: 60
Study 26521575 — intervention group
Group type: COMPARATOR
Intervention: Simple rehabilitation training
Number of subjects: 60
Study 22901492 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led unit (MU)
Number of subjects: 1110
Study 22901492 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric unit (SCU)
Number of subjects: 1110
Study 20479480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (n = 30)
Number of subjects: 59
Study 20479480 — intervention group
Group type: COMPARATOR
Intervention: Video attention-control (n = 29)
Number of subjects: 59
Study 19047704 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 173
Study 19047704 — intervention group
Group type: COMPARATOR
Intervention: Bracing
Number of subjects: 173
Study 19047704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical trial participation
Number of subjects: 173
Study 19047704 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making responsibility
Number of subjects: 173
Study 19047704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 173
Study 16463842 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon‐enhanced computerized tomography (Xe‐CT)
Number of subjects: 43
Study 12576441 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40 positive group
Number of subjects: 125
Study 12576441 — intervention group
Group type: EXPERIMENTAL
Intervention: CD23 positive group
Number of subjects: 125
Study 10326966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome
Number of subjects: 777
Study 10326966 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related macular degeneration
Number of subjects: 777
Study 7491349 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 85
Study 7491349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LTOT)
Number of subjects: 85
Study 1685841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Actiderm) plus triamcinolone acetonide (TAA) 0.1% cream applied every third day
Number of subjects: 19
Study 1685841 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% cream applied twice daily for 4 weeks
Number of subjects: 19
Study 1685841 — intervention group
Group type: EXPERIMENTAL
Intervention: Actiderm plus TAA
Number of subjects: 19
Study 7199333 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 7199333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 7199333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataralgesic combinations
Number of subjects: 0
Study 28758261 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond lasers
Number of subjects: 49
Study 28758261 — intervention group
Group type: COMPARATOR
Intervention: Nanosecond laser
Number of subjects: 49
Study 28758261 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond lasers (monochromic black or blue tattoos)
Number of subjects: 49
Study 28758261 — intervention group
Group type: COMPARATOR
Intervention: Nanosecond laser (monochromic black or blue tattoos)
Number of subjects: 49
Study 28758261 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond lasers (polychromic tattoos)
Number of subjects: 49
Study 28758261 — intervention group
Group type: COMPARATOR
Intervention: Nanosecond laser (polychromic tattoos)
Number of subjects: 49
Study 27140187 — intervention group
Group type: EXPERIMENTAL
Intervention: No area under the noseband (NAUN)
Number of subjects: 12
Study 27140187 — intervention group
Group type: EXPERIMENTAL
Intervention: Half conventional area under noseband (HCAUN)
Number of subjects: 12
Study 27140187 — intervention group
Group type: COMPARATOR
Intervention: Unfastened noseband (UN)
Number of subjects: 12
Study 27140187 — intervention group
Group type: COMPARATOR
Intervention: Conventional area under noseband (CAUN)
Number of subjects: 12
Study 27140187 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-removal of noseband and double bridle
Number of subjects: 12
Study 24731567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-dose atorvastatin therapy (IAT, 40mg/day)
Number of subjects: 120
Study 24731567 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose atorvastatin therapy (SAT, 20mg/day)
Number of subjects: 120
Study 24731567 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atorvastatin therapy (LAT, 10mg/day)
Number of subjects: 120
Study 24731567 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (IAT, SAT, LAT)
Number of subjects: 120
Study 22466997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P)
Number of subjects: 85
Study 22466997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P1, n = 33)
Number of subjects: 85
Study 22466997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P1)
Number of subjects: 85
Study 22466997 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (Group NP)
Number of subjects: 85
Study 19936872 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, chlorhexidine gel 0.5%, three sessions of KTP laser irradiation
Number of subjects: 730
Study 19936872 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, three sessions of KTP laser irradiation
Number of subjects: 730
Study 19936872 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, irrigation with povidone-iodine 10%, three sessions of KTP laser irradiation
Number of subjects: 730
Study 19936872 — intervention group
Group type: COMPARATOR
Intervention: SRP, chlorhexidine gel 0.5%
Number of subjects: 730
Study 18024088 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 44
Study 18024088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15964561 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance testing for CRP and WBC
Number of subjects: 305
Study 15964561 — intervention group
Group type: COMPARATOR
Intervention: No advance testing
Number of subjects: 305
Study 12601104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sumatriptan nasal spray
Number of subjects: 118
Study 12601104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 10229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oxycodone
Number of subjects: 167
Study 10229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone-APAP
Number of subjects: 167
Study 10229408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 8740103 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg b.i.d. 5 days for 3 weeks
Number of subjects: 36
Study 8740103 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet 90 mg/kg b.i.d. daily (7 days a week)
Number of subjects: 36
Study 8740103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 36
Study 1928165 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded PA catheters made of polyvinylchloride or polyurethane
Number of subjects: 297
Study 1928165 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded PA catheters
Number of subjects: 297
Study 6351455 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfenefrin infusion (2-4 mg/kg per minute)
Number of subjects: 12
Study 31596615 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (PE) for 20 minutes in underwater conditions (WET)
Number of subjects: 27
Study 31596615 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical exercise (PE) for 20 minutes in underwater conditions (WET)
Number of subjects: 27
Study 31596615 — intervention group
Group type: COMPARATOR
Intervention: Inactivity (DRY) in laboratory conditions
Number of subjects: 27